1-(Oxolan-3-yl)piperazine dihydrochloride

Catalog No.: 
ACUAGF470
CAS No.: 
1461714-60-2
Molecular Formula: 
C8H18Cl2N2O
Molecular Weight: 
229.15
1-(Oxolan-3-yl)piperazine dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$157.00In stockInquiry
250mg95%$313.00In stockInquiry
500mg95%$469.00In stockInquiry
1g95%$781.00In stockInquiry
5g95%$2343.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(Oxolan-3-yl)piperazine dihydrochloride
IUPAC Name1-(tetrahydrofuran-3-yl)piperazine dihydrochloride
MDL No.MFCD26407512
Molecular FormulaC8H18Cl2N2O
Molecular Weight229.15
SMILES[H]Cl.[H]Cl.N1(C2COCC2)CCNCC1
InChI KeySNWUJSXQXGRRQE-UHFFFAOYSA-N
SynonymPiperazine, 1-(tetrahydro-3-furanyl)-, hydrochloride (1:2);1-tetrahydrofuran-3-ylpiperazine dihydrochloride
CAS No.1461714-60-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Synthetic Route by SureRoute

1. ACUAGF470 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7In Stock
  2. Plus
  3. ACHJGS164 route compound structure diagram
    ACHJGS164453-20-3In Stock
  4. Then
  5. ACUAGF470 route product structure diagram
    ACUAGF4701461714-60-2In Stock
Inquiry

2. ACUAGF470 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUAGF470 route product structure diagram
    ACUAGF4701461714-60-2In Stock
Inquiry

3. ACUAGF470 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUAGF470 route product structure diagram
    ACUAGF4701461714-60-2In Stock
Inquiry

Comments (0)